Details
| Titel in Übersetzung | The prevention of nursing costs for Alzheimer’s disease with Galantamine |
|---|---|
| Originalsprache | Mehrere Sprachen |
| Seiten (von - bis) | 145-151 |
| Seitenumfang | 7 |
| Fachzeitschrift | Pravention und Gesundheitsforderung |
| Jahrgang | 3 |
| Ausgabenummer | 3 |
| Frühes Online-Datum | 3 Juli 2008 |
| Publikationsstatus | Veröffentlicht - Aug. 2008 |
Abstract
Aim. The aim of this paper is to systematically review health-economic evidence for treating Alzheimer's disease with galantamine. Methods. First, a structured literature search of relevant databases was conducted. In a second step, all hits were screened for their content and were evaluated separately by two different researchers. Subsequently, a structured review of all relevant papers was prepared. Results. Of the initial 197 search results, eight health-economic studies were found to methodologically and thematically match with the study question. The results of all evaluated studies suggest an economic efficiency for treating Alzheimer's disease with galantamine, although all studies face certain limitations; most of the underlying models made specific assumptions, resulting in additional uncertainty around the respective results. Conclusion. Despite ongoing medical research in this area, galantamine, as compared with no drug therapy, can be considered an economically reasonable treatment alternative within the German health care system. Additional studies evaluating some of the models' assumptions must be conducted in the future to further support these findings.
Schlagwörter
- Alzheimer's disease, Economic, Galantamine, Systematic review
ASJC Scopus Sachgebiete
- Medizin (insg.)
- Öffentliche Gesundheit, Umwelt- und Arbeitsmedizin
Ziele für nachhaltige Entwicklung
Zitieren
- Standard
- Harvard
- Apa
- Vancouver
- BibTex
- RIS
in: Pravention und Gesundheitsforderung, Jahrgang 3, Nr. 3, 08.2008, S. 145-151.
Publikation: Beitrag in Fachzeitschrift › Artikel › Forschung › Peer-Review
}
TY - JOUR
T1 - Die Vermeidung von Pflegekosten bei der Alzheimer-Erkrankung durch Galantamin
AU - Braun, S.
AU - Greiner, W.
AU - Von Der Schulenburg, J. M.
PY - 2008/8
Y1 - 2008/8
N2 - Aim. The aim of this paper is to systematically review health-economic evidence for treating Alzheimer's disease with galantamine. Methods. First, a structured literature search of relevant databases was conducted. In a second step, all hits were screened for their content and were evaluated separately by two different researchers. Subsequently, a structured review of all relevant papers was prepared. Results. Of the initial 197 search results, eight health-economic studies were found to methodologically and thematically match with the study question. The results of all evaluated studies suggest an economic efficiency for treating Alzheimer's disease with galantamine, although all studies face certain limitations; most of the underlying models made specific assumptions, resulting in additional uncertainty around the respective results. Conclusion. Despite ongoing medical research in this area, galantamine, as compared with no drug therapy, can be considered an economically reasonable treatment alternative within the German health care system. Additional studies evaluating some of the models' assumptions must be conducted in the future to further support these findings.
AB - Aim. The aim of this paper is to systematically review health-economic evidence for treating Alzheimer's disease with galantamine. Methods. First, a structured literature search of relevant databases was conducted. In a second step, all hits were screened for their content and were evaluated separately by two different researchers. Subsequently, a structured review of all relevant papers was prepared. Results. Of the initial 197 search results, eight health-economic studies were found to methodologically and thematically match with the study question. The results of all evaluated studies suggest an economic efficiency for treating Alzheimer's disease with galantamine, although all studies face certain limitations; most of the underlying models made specific assumptions, resulting in additional uncertainty around the respective results. Conclusion. Despite ongoing medical research in this area, galantamine, as compared with no drug therapy, can be considered an economically reasonable treatment alternative within the German health care system. Additional studies evaluating some of the models' assumptions must be conducted in the future to further support these findings.
KW - Alzheimer's disease
KW - Economic
KW - Galantamine
KW - Systematic review
UR - http://www.scopus.com/inward/record.url?scp=49749135494&partnerID=8YFLogxK
U2 - 10.1007/s11553-008-0121-5
DO - 10.1007/s11553-008-0121-5
M3 - Article
AN - SCOPUS:49749135494
VL - 3
SP - 145
EP - 151
JO - Pravention und Gesundheitsforderung
JF - Pravention und Gesundheitsforderung
SN - 1861-6755
IS - 3
ER -